Innovent Biologics (HKEX: 01801) says its thyroid eye disease drug works in a group of patients that doctors have rarely been able to treat with medicine at all.

In a release dated October 8, 2026, the Suzhou-based company reported that a Phase 3 trial of Sycume (teprotumumab N01, research code IBI311) met its primary endpoint in Chinese adults with inactive thyroid eye disease (TED). These are people whose eye inflammation has died down but left the eyes pushed forward. For them, surgery has long been the main option.

The numbers are topline. The full dataset hasn’t been presented or peer-reviewed yet. And the release doesn’t say what Innovent plans to do with the results on the regulatory front.

A Disease That Burns Out but Leaves Damage

TED is an autoimmune condition. The immune system attacks the muscle and fatty tissue behind the eyes, which swell and remodel. Innovent’s release says it affects roughly 25% to 40% of people with Graves’ disease, an autoimmune thyroid disorder.

It runs in two phases. The active phase brings redness, swelling and pain. Eventually it settles into an inactive, or chronic, phase. The inflammation fades. The structural damage often doesn’t. That includes proptosis, the medical term for bulging eyes, and sometimes double vision.

Citing a 2024 European study, Innovent says inactive patients make up about two-thirds of the TED population. That’s a large group with few drug options.

Inside RESTORE-3

RESTORE-3 was a multicenter, randomized, double-blind, placebo-controlled trial in China. It enrolled 116 adults whose Clinical Activity Score (CAS), a 7-point scale for grading eye inflammation, was 2 or lower in both eyes. About 74.1% scored 0 or 1. On average, they’d had the disease for 4.3 years. Patients were randomized roughly 2:1 to Sycume or placebo.

The primary endpoint was the proptosis response rate in the study eye at Week 24, meaning the share of patients whose bulging improved past a set threshold. The release doesn’t define that threshold. In comparable Tepezza trials, it was a reduction of at least 2 mm.

At Week 24, 60.4% of Sycume patients responded versus 23.5% on placebo, a 36.9-point gap (p = 0.0003). The key secondary endpoint, average change in bulging, came in at -1.88 mm for Sycume versus -0.88 mm for placebo. That’s a placebo-adjusted difference of 1.00 mm (p < 0.0001).

The other eye, which wasn’t the primary focus, moved the same way: a 46.0% response rate versus 19.8% (p = 0.0071), and a -1.77 mm change versus -0.91 mm (p < 0.0001).

Is a one-millimeter edge over placebo meaningful? The lead investigator, Professor Zhongyan Shan of the First Hospital of China Medical University, called the reductions robust and clinically meaningful. That’s the investigator’s view. The full dataset will let others judge for themselves.

Safety Details Are Thin

Innovent says most treatment-emergent adverse events were mild to moderate and that no new safety signals appeared. That’s the whole safety section.

No event rates. No discontinuation figures. No mention of hearing or blood sugar.

Those gaps stand out. In the U.S., Tepezza’s label lists hyperglycemia (added in December 2022) and hearing impairment (added in July 2023) among its warnings, noting that hearing loss may in some cases be permanent. Lumvoa, another IGF-1R drug, carries similar warnings. Whether Sycume showed any of these signals in RESTORE-3 can’t be judged from the release.

Same Name, Different Drug

Sycume’s generic name, teprotumumab N01, closely mirrors teprotumumab-trbw, the active ingredient in Tepezza, which Amgen (Nasdaq: AMGN) now markets after acquiring Horizon Therapeutics. They are separate products from separate companies. Innovent describes Sycume as independently developed. Keep the two apart when reading headlines.

Tepezza Covered This Ground First

Inactive TED isn’t uncharted territory. In April 2023, the FDA updated Tepezza’s label to cover TED regardless of disease activity or duration. That followed a Phase 4 trial in 62 patients with long-standing, low-CAS disease. Horizon reported that about 62% of Tepezza patients achieved a proptosis response versus 25% on placebo, with an average reduction of 2.41 mm versus 0.92 mm.

Innovent cites those Tepezza results itself and calls RESTORE-3 “generally consistent” with them. It also concedes the comparison is indirect and that its own patients started with less bulging (22.16 mm on average). That caveat matters. These were different trials in different populations, never run head-to-head. Any side-by-side reading is suggestive, not proof.

A Superlative That Has Aged

Innovent again describes Sycume as China’s first IGF-1R antibody drug and the second approved anywhere in the world. When China’s National Medical Products Administration (NMPA) cleared it in March 2025, both points held. Tepezza was the only other approved drug of its kind, and it wasn’t available in China.

By date, Sycume is still second. But the framing skips a newer arrival. On June 26, 2026, the FDA approved Viridian Therapeutics’ (Nasdaq: VRDN) Lumvoa (veligrotug-vvze), an IGF-1R antibody labeled for TED regardless of activity or duration. The class now has at least three approved drugs.

What Investors Should Watch

Sycume joined China’s National Reimbursement Drug List on January 1, 2026, which should widen access at home. The release gives no sales figures.

Several things are missing. There’s no timeline for any regulatory submission based on RESTORE-3. There’s no word on whether the existing Chinese approval already covers inactive patients or needs an update. And there’s no mention of plans to take Sycume outside China, despite the release’s San Francisco dateline.

Follow-up is ongoing. Innovent says complete results will appear at future medical conferences or in peer-reviewed journals. Until then, this is a company-reported topline readout from a 116-patient trial. Solid on its face. Not the final word.

This article covers clinical trial data and is not medical or investment advice.

Sources

• Innovent Biologics: Innovent Announces Phase 3 RESTORE-3 Study of SYCUME (Teprotumumab N01 Injection) Met Primary Endpoint in Inactive Thyroid Eye Disease, PRNewswire, October 8, 2026. Primary source release.
• Pharmaceutical Technology: China’s First IGF-1R Monoclonal Antibody, Innovent Announces NMPA Approval of SYCUME for the Treatment of Thyroid Eye Disease, cited for Sycume’s March 2025 NMPA approval and the fact that Tepezza was not available in China at the time.
• Pharmaceutical Technology: FDA Approves Update to Horizon’s Tepezza Label for TED, cited for the April 2023 label update covering TED regardless of disease activity or duration.
• Eyes On Eyecare (Glance): Positive Data Reported for Phase 4 Study on Tepezza for TED, cited for the Tepezza chronic, low-CAS Phase 4 trial size, response rates, and mean proptosis change.
• Medthority: Initiation of Phase III Trial in Japan Evaluating Tepezza in Chronic/Low CAS Thyroid Eye Disease, cited for the standard 2 mm proptosis response definition used in Tepezza trials, which the Innovent release did not define.
• Eyes On Eyecare (Glance): FDA Adds New Warning to Tepezza Label, cited for the hyperglycemia (December 2022) and hearing impairment (July 2023) warnings on Tepezza’s U.S. label, which the Innovent release did not address.
• HCPLive: FDA Approves Veligrotug-vvze for Thyroid Eye Disease, cited for Lumvoa’s June 26, 2026 FDA approval and its labeled warnings, used for competitive-landscape context.

Editorial Disclosure

This article reports on topline Phase 3 clinical trial data announced by Innovent Biologics, Inc. in a press release issued on October 8, 2026, regarding SYCUME (teprotumumab N01, IBI311). Securities and companies discussed: Innovent Biologics, Inc. (HKEX: 01801), Amgen Inc. (Nasdaq: AMGN), and Viridian Therapeutics, Inc. (Nasdaq: VRDN). Context on Tepezza’s U.S. label history, safety warnings, and Phase 4 data, on Lumvoa’s FDA approval, and on SYCUME’s March 2025 NMPA approval was drawn from the independent sources cited above, since the original release did not address these points. BioTech Stocks Daily has not received, nor will it accept, any compensation, direct or indirect, from Innovent Biologics, Amgen, Viridian Therapeutics, or any other corporate or third-party sponsor for the preparation or publication of this coverage. No staff member, principal, or affiliate of BioTech Stocks Daily holds a position, option, or financial interest in any of the securities mentioned as of the date of publication. Statements regarding future regulatory submissions, potential label updates, publication of full trial data, commercial uptake, and competitive positioning are forward-looking statements. They involve substantial risks, regulatory uncertainties, and scientific variables; actual clinical outcomes, development timelines, and commercial results may differ materially. Biotechnology investments carry a high degree of financial risk. Drug development and commercialization are subject to clinical failure, regulatory setbacks, safety findings, and market competition, which can result in the loss of invested capital. This article is published strictly for independent news reporting, market context, and educational purposes only. It does not constitute an investment recommendation, endorsement, or professional financial, legal, or tax advice. Furthermore, this content is not medical advice; patients and healthcare providers should consult appropriate clinical professionals for medical guidance.

For full details regarding our editorial independence, publishing policies, and comprehensive risk disclaimers, please see our full DISCLAIMER.